Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of FCF Margin readings, the most recent being 595.54% for Q1 2026.

  • On a quarterly basis, FCF Margin fell 56687.0% to 595.54% in Q1 2026 year-over-year; TTM through Mar 2026 was 111.82%, a 7810.0% decrease, with the full-year FY2025 number at 42.18%, up 1131.0% from a year prior.
  • FCF Margin hit 595.54% in Q1 2026 for Atara Biotherapeutics, down from 357.18% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 9.93% in Q3 2024 to a low of 25749.32% in Q4 2022.
  • Median FCF Margin over the past 5 years was 320.31% (2025), compared with a mean of 2612.64%.
  • The widest YoY moves for FCF Margin: up 2471327bps in 2023, down -649909bps in 2023.
  • Atara Biotherapeutics' FCF Margin stood at 25749.32% in 2022, then surged by 96bps to 1036.05% in 2023, then surged by 93bps to 74.99% in 2024, then tumbled by -376bps to 357.18% in 2025, then plummeted by -67bps to 595.54% in 2026.
  • The last three reported values for FCF Margin were 595.54% (Q1 2026), 357.18% (Q4 2025), and 283.43% (Q3 2025) per Business Quant data.